血清胸腺因子抗EAC瘤、H22瘤、W256瘤作用的初探  

Initial study on anticancer effect of serum thymic factor

作　　者：张长平[1] 乐嘉静[2] 李湛君[2] 徐康森[2] 

机构地区：[1]南京医科大学 [2]中国药品生物制品检定所,北京100050

出　　处：《中国临床药理学与治疗学》2007年第6期668-671,共4页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的:观察血清胸腺因子(FTS)对荷瘤小鼠的抑瘤作用。方法:荷EAC瘤小鼠、荷H22瘤小鼠、荷W256瘤大鼠分别皮下注射给予不同剂量的FTS,测定其生命延长率和抑瘤率,并测定T细胞增殖能力、迟发型超敏反应等免疫指标。结果:荷EAC、H22瘤小鼠注射FTS0.25、0.13mg/kg剂量后生命延长率或抑瘤率均大于30%,生存天数和瘤重与阴性对照组(NS)比较有统计学差异(P<0.01);荷W256瘤大鼠FTS各组瘤重与NS组比较均有统计学差异(P<0.01),抑瘤率均大于30%。另外,伴刀豆球蛋白A(ConA)刺激后0.016mg/mL处刺激指数最大。迟发型超敏反应亦呈现阳性结果。结论:FTS对EAC瘤、H22瘤、W256瘤均具有一定的抑制作用。To study the inhibitory effect of serum thymic factor （FIS） on cancer cells. METHODS： Bearing cancer mice, rats were administrated with different dosages of FIS. Life extension rate and inhibitory rate were determined. Stimulation index （SI） and delayed hypersensitivity were observed, too. RESULTS： Life extension rate or inhibitory rate in mice exceeded 30% in 0.25 mg/kg group and 0.13 mg/kg group, and those parameters in rats also exceeded 30% in FTS three groups. After Con-A stimulation, SI achieved maximum at 0.016 mg/mL. Delayed hypersensitivity also showed positive results. CONCLUSION： FTS has significant inhibitory effect on the growth of EAC, H22 and W256 cancer cells.

关 键 词：血清胸腺因子 抑瘤率 生命延长率 免疫增强 

分 类 号：R965.2[医药卫生—药理学]